Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | IDE | P14735 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | HLCS | P50747 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 8/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | CA9 | Q16790 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL1269621 | 0.99 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1269623 | 0.91 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL2484400 | 0.91 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3378125 | 0.90 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3142794 | 0.87 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL723192 | 0.86 | TDP1 (0.90) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1199492 | 0.86 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL636444 | 0.86 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.86 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 0.86 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024077174-A1 | METHODS FOR CULTURING NR4A-DEFICIENT CELLS | LYELL IMMUNOPHARMA, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023147185-A9 | METHODS FOR MAKING AND USING ANTIGEN-PRESENTING CELL-MIMETIC SCAFFOLDS TO ENHANCE T-CELL THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230357313-A1 | SERUM RESISTANT BIS-SULFHYDRYL SPECIFIC BIOTINYLATION REAGENT | Miltenyi Biotec B.V. & Co. KG (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230340404-A1 | ANTIGEN-PRESENTING CELL-MIMETIC SCAFFOLDS AND METHODS FOR MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4234559-A1 | SERUM RESISTANT BIS-SULFHYDRYL SPECIFIC BIOTINYLATION REAGENT | Miltenyi Biotec B.V. & Co. KG (DE) | 2023-08-30 | — | — | EP | disclosed |
| CN-116640151-A | Serum-resistant dimercapto-specific biotinylation reagent | 美天施生物科技有限两合公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023147185-A1 | METHODS FOR MAKING AND USING ANTIGEN-PRESENTING CELL-MIMETIC SCAFFOLDS TO ENHANCE T-CELL THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230181644-A1 | METHODS OF GENERATING CELLS | LYELL IMMUNOPHARMA, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023076511-A1 | METHODS OF GENERATING CELLS | LYELL IMMUNOPHARMA, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11555177-B2 | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-17 | — | — | US | disclosed |
| US-5690907-A | Avidin-biotin conjugated emulsions as a site specific binding system | THE JEWISH HOSPITAL OF ST. LOUIS (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0544759-B1 | DETOXIFICATION OF SOIL | YAMASHITA THOMAS T (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996041647-A1 | SITE SPECIFIC BINDING SYSTEM, IMAGING COMPOSITIONS AND METHODS | BARNES-JEWISH HOSPITAL D/B/A (US) | 1996-12-27 | — | — | WO | disclosed |
| US-5582627-A | TREATMENT OF SOIL CONTAMINATED WITH HERBICIDES AND PESTICIDES COMPRISING ADDING NUTRIENT MEDIUM, COMPLEXING MEDIUM, NITROGEN AND PHOSPHORUS NUTRIENTS | YAMASHITA THOMAS T (US) | 1996-12-10 | — | — | US | disclosed |
| US-5549729-A | CONSISTS OF CARBON SKELETON/ENERGY COMPONENT, MACRONUTRIENT COMPONENT AND VITAMIN/COFACTOR COMPONENT; SUITABLE FOR FOLIAR SPRAYS | YAMASHITA THOMAS T (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0433394-B1 | METHOD OF APPLYING ENERGY, CARBON SKELETON AND NUTRIENT MATERIALSTO VEGETATION | YAMASHITA THOMAS T (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0544759-A4 | DETOXIFICATION OF SOIL | YAMASHITA THOMAS T (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0544759-A1 | DETOXIFICATION OF SOIL. | YAMASHITA THOMAS T (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992003393-A1 | DETOXIFICATION OF SOIL | YAMASHITA THOMAS T (US) | 1992-03-05 | — | — | WO | disclosed |
| WO-1991013844-A1 | METHOD AND COMPOSITION FOR PROMOTING AND CONTROLLING GROWTH OF PLANTS | YAMASHITA THOMAS T (US) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357313-A1 | SERUM RESISTANT BIS-SULFHYDRYL SPECIFIC BIOTINYLATION REAGENT | BTD, HLCS, CBS | TDP1 4782/4885MEN1 3517/4885ABL1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.